Crispr Therapeutics AG (1CG) AI Stock Analysis

2 Followers

Crispr Therapeutics AG

(BX Swiss:1CG)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

CRISPR Gene-Editing PlatformA focused CRISPR/Cas9 platform and broad therapeutic pipeline provide a reusable foundation for multiple programs rather than reliance on one asset. Progress across hematology, oncology and other disease areas could diversify future product opportunities and support longer-term strategic value.

Negative Factors

Persistent Cash BurnMaterial operating and free-cash-flow deficits show that current activities consume substantial cash rather than funding themselves. If this burn persists, the company may face increasing pressure to preserve spending, secure additional capital or rely more heavily on partnership proceeds.

Crispr Therapeutics AG (1CG) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 4.44B
Dividend Yield: ―
Average Volume (3M): 885
Price to Earnings (P/E): -9.7
Beta (1Y): 0.19
Revenue Growth: -39.86%
EPS Growth: 19.88%
Country: Switzerland
Employees: 393
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associat...

Crispr Therapeutics AG Risk Analysis

Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Crispr Therapeutics AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:1CG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LEGN	72Outperform	$3.95B	-1954.00	-0.02%	―	49.73%	98.75%
KYMR	60Neutral	$11.67B	-37.15	-22.39%	―	133.77%	-0.64%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NTLA	51Neutral	$1.57B	-3.40	-64.73%	―	-8.07%	21.55%
BEAM	46Neutral	$2.60B	-25.81	-9.69%	―	163.27%	77.49%

* Healthcare Sector Average

Performance Comparison

CH:1CG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:1CG	Crispr Therapeutics	39.80	-5.25	-11.66%
NTLA	Intellia Therapeutics Inc	11.41	2.74	31.60%
BEAM	Beam Therapeutics, Inc.	25.81	4.15	19.16%
LEGN	Legend Biotech Corporation	19.54	-11.47	-36.99%
KYMR	Kymera Therapeutics, Inc.	134.84	71.21	111.91%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Crispr Therapeutics AG AI Stock Analysis